On May 20, 2020, Kindred Biosciences announced it had entered into an agreement with Vaxart for the manufacture of Vaxart’s oral vaccine candidate for COVID-19. KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices, and provide it to Vaxart to be formulated into a vaccine tablet to be taken by mouth instead of by needle injection.